SinuSys Corporation, a sinus health company, announced that it has received clearance from the U.S. Food and Drug Administration for its Vent-Os Sinus Dilation System, which is designed to resolve sinusitis symptoms in a two-step interventional procedure.
The device enables low-pressure, gradual dilation of the maxillary sinus ostia, which is intended to help patients tolerate the procedure in an office setting under local anesthesia.
The Vent-Os system has also received the CE Mark, Health Canada license and Australian Therapeutic Goods Administration Certificate.
First Navio Unicondylar Knee Replacement Performed in France
Abrams Royal Pharmacy Issues Voluntary Recall on All Unexpired Sterile Products
The device enables low-pressure, gradual dilation of the maxillary sinus ostia, which is intended to help patients tolerate the procedure in an office setting under local anesthesia.
The Vent-Os system has also received the CE Mark, Health Canada license and Australian Therapeutic Goods Administration Certificate.
More Articles on Supply Chain:
Reducing Supply Chain CostsFirst Navio Unicondylar Knee Replacement Performed in France
Abrams Royal Pharmacy Issues Voluntary Recall on All Unexpired Sterile Products